

# Nancy L Bartlett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1662737/publications.pdf>

Version: 2024-02-01

369  
papers

29,635  
citations

9756

73  
h-index

5519

163  
g-index

375  
all docs

375  
docs citations

375  
times ranked

20724  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2531-2544.  | 13.9 | 3,865     |
| 2  | Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1â€“2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 31-42.   | 5.1  | 1,467     |
| 3  | Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1396-1407.  | 13.9 | 1,443     |
| 4  | Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2183-2189.  | 0.8  | 1,332     |
| 5  | Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. <i>New England Journal of Medicine</i> , 2010, 363, 1812-1821.   | 13.9 | 1,266     |
| 6  | Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 2425-2437.   | 13.9 | 1,261     |
| 7  | Randomized Controlled Trial of Yttrium-90â€“Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkinâ€™s Lymphoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2453-2463. | 0.8  | 1,069     |
| 8  | Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2190-2196.   | 0.8  | 890       |
| 9  | CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkinâ€™s Lymphoma. <i>New England Journal of Medicine</i> , 2018, 379, 1711-1721.   | 13.9 | 796       |
| 10 | Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018, 379, 2517-2528.   | 13.9 | 706       |
| 11 | Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkinâ€™s Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 331-344.  | 13.9 | 564       |
| 12 | Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 229-240.   | 6.3  | 517       |
| 13 | Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. <i>Molecular Therapy</i> , 2017, 25, 285-295.   | 3.7  | 498       |
| 14 | Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. <i>Lancet Oncology</i> , The, 2016, 17, 200-211.        | 5.1  | 373       |
| 15 | Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. <i>Blood</i> , 2014, 123, 3095-3100.  | 0.6  | 280       |
| 16 | Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 1183-1194.   | 0.6  | 276       |
| 17 | Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. <i>Journal of Clinical Oncology</i> , 2019, 37, 1790-1799.   | 0.8  | 266       |
| 18 | Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2018, 379, 934-947.   | 13.9 | 264       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 630-637.   | 0.8 | 261       |
| 20 | Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. <i>Blood</i> , 2002, 99, 4336-4342.   | 0.6 | 257       |
| 21 | Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Journal of Clinical Oncology</i> , 2013, 31, 684-691. | 0.8 | 256       |
| 22 | Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. <i>Blood</i> , 2015, 125, 1394-1402.   | 0.6 | 242       |
| 23 | US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016, 34, 2020-2027.                                 | 0.8 | 239       |
| 24 | A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. <i>British Journal of Haematology</i> , 2009, 146, 171-179.   | 1.2 | 230       |
| 25 | Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2010, 116, 106-114.   | 2.0 | 217       |
| 26 | A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2012, 18, 248-255.   | 3.2 | 204       |
| 27 | Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. <i>Blood</i> , 2003, 101, 4285-4289.  | 0.6 | 191       |
| 28 | A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. <i>Blood</i> , 2008, 111, 1848-1854.  | 0.6 | 189       |
| 29 | Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. <i>Blood</i> , 2012, 120, 3280-3287.  | 0.6 | 188       |
| 30 | Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909. <i>Journal of Clinical Oncology</i> , 2009, 27, 6101-6108.  | 0.8 | 182       |
| 31 | A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. <i>Blood</i> , 2011, 118, 5119-5125.   | 0.6 | 181       |
| 32 | Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 692-700.   | 0.8 | 176       |
| 33 | Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. <i>Blood</i> , 2017, 130, 2709-2717.   | 0.6 | 176       |
| 34 | Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 3635-3640.   | 0.8 | 163       |
| 35 | Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin, a radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 39, 181-194.               | 2.0 | 161       |
| 36 | Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). <i>Blood</i> , 2015, 126, 851-857.  | 0.6 | 161       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 481-491.  | 0.8  | 160       |
| 38 | Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30 <sup>+</sup> Peripheral T-Cell Lymphomas: Results of a Phase I Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3137-3143.   | 0.8  | 153       |
| 39 | Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and Tj ETQq1 1 0.784314 rgBT /Overlode) prospective, multicentre, single-arm phase 2 study. <i>Lancet Haematology</i> , 2018, 5, e609-e617.  | 2.2  | 152       |
| 40 | Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. <i>Blood</i> , 2019, 134, 6-6. | 0.6  | 152       |
| 41 | <sup>18</sup> F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation. <i>Journal of Nuclear Medicine</i> , 2011, 52, 386-392.  | 2.8  | 151       |
| 42 | Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. <i>Blood</i> , 2017, 129, 473-483.   | 0.6  | 147       |
| 43 | Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. <i>Journal of Hematology and Oncology</i> , 2014, 7, 24.   | 6.9  | 144       |
| 44 | <i>In Situ</i> Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. <i>Cancer Discovery</i> , 2018, 8, 1258-1269.   | 7.7  | 136       |
| 45 | CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. <i>Blood</i> , 2020, 136, 2308-2318.   | 0.6  | 133       |
| 46 | The IL-15-Based ALT-803 Complex Enhances Fc $\gamma$ RIIIa-Triggered NK Cell Responses and <i>In Vivo</i> Clearance of B Cell Lymphomas. <i>Clinical Cancer Research</i> , 2016, 22, 596-608.  | 3.2  | 130       |
| 47 | Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. <i>Blood</i> , 2018, 131, 182-190.   | 0.6  | 130       |
| 48 | Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. <i>Journal of Clinical Oncology</i> , 2016, 34, 1620-1625.        | 0.8  | 121       |
| 49 | Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. <i>Lancet Oncology</i> , 2022, 23, 1055-1065.  | 5.1  | 119       |
| 50 | Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. <i>Blood</i> , 2013, 121, 3547-3553.  | 0.6  | 117       |
| 51 | The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and <sup>137</sup> cesium in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. <i>British Journal of Haematology</i> , 2013, 161, 76-86.        | 1.2  | 111       |
| 52 | Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. <i>Haematologica</i> , 2018, 103, 1502-1510.   | 1.7  | 111       |
| 53 | Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. <i>Blood</i> , 2021, 138, 427-438.   | 0.6  | 109       |
| 54 | Hodgkin lymphoma. <i>Nature Reviews Disease Primers</i> , 2020, 6, 61.   | 18.1 | 103       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492. <i>Journal of Clinical Oncology</i> , 2000, 18, 972-972.                           | 0.8  | 101       |
| 56 | Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted <sc>EPOCH</sc>. <i>British Journal of Haematology</i> , 2017, 179, 739-747.  | 1.2  | 101       |
| 57 | Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b "2 study. <i>Lancet Oncology</i> , The, 2019, 20, 998-1010.                    | 5.1  | 101       |
| 58 | NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1218-1230.   | 2.3  | 98        |
| 59 | Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2022, 387, 310-320.  | 13.9 | 98        |
| 60 | Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>Journal of Clinical Oncology</i> , 2015, 33, 2399-2404.  | 0.8  | 97        |
| 61 | Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 912-918.  | 0.8  | 96        |
| 62 | A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. <i>Cancer</i> , 2012, 118, 3128-3134.  | 2.0  | 95        |
| 63 | Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 4132-4139.   | 0.8  | 93        |
| 64 | Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2519-2529.   | 0.8  | 93        |
| 65 | Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1646-1652. | 2.0  | 92        |
| 66 | A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2020, 136, 2401-2409.   | 0.6  | 92        |
| 67 | CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. <i>Blood</i> , 2018, 132, 1013-1021.  | 0.6  | 90        |
| 68 | Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. <i>Blood</i> , 2020, 135, 2106-2109.   | 0.6  | 90        |
| 69 | Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021, 194, 690-700.   | 1.2  | 88        |
| 70 | Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 1238-1246.   | 0.6  | 86        |
| 71 | Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020, 135, 735-742.  | 0.6  | 86        |
| 72 | Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , the, 2021, 8, e410-e421.                       | 2.2  | 83        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. <i>Blood</i> , 2016, 128, 469-469.  | 0.6 | 79        |
| 74 | Increased Body Mass Index Is Associated With Improved Survival in United States Veterans With Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 3217-3222.   | 0.8 | 78        |
| 75 | Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. <i>Lancet Haematology</i> , 2017, 4, e176-e182.                        | 2.2 | 77        |
| 76 | Assessment of Cellular Proliferation in Tumors by PET Using <sup>18</sup> F-ISO-1. <i>Journal of Nuclear Medicine</i> , 2013, 54, 350-357.  | 2.8 | 76        |
| 77 | A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. <i>Journal of Hematology and Oncology</i> , 2014, 7, 44.   | 6.9 | 76        |
| 78 | Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1797-1803.   | 0.8 | 75        |
| 79 | Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020, 38, 3003-3011.                     | 0.8 | 75        |
| 80 | Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort. <i>American Journal of Hematology</i> , 2015, 90, 778-783. | 2.0 | 71        |
| 81 | A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 1059-1066.  | 3.2 | 71        |
| 82 | High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2014, 55, 1345-1349.   | 0.6 | 67        |
| 83 | Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206. <i>Leukemia and Lymphoma</i> , 2007, 48, 1313-1319.   | 0.6 | 64        |
| 84 | A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). <i>European Journal of Cancer</i> , 2016, 54, 11-17.   | 1.3 | 63        |
| 85 | Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. <i>Blood</i> , 2020, 135, 2224-2234.   | 0.6 | 62        |
| 86 | A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. <i>Blood</i> , 2019, 133, 1201-1204.  | 0.6 | 58        |
| 87 | Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. <i>Blood</i> , 2011, 117, 5314-5320.   | 0.6 | 56        |
| 88 | Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. <i>Blood</i> , 2016, 128, 2510-2516.   | 0.6 | 56        |
| 89 | Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. <i>Blood</i> , 2018, 131, 2120-2124.   | 0.6 | 56        |
| 90 | Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e808-e815.                                  | 2.2 | 55        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Interim [ <sup>18</sup> F]fluorodeoxyglucose positron emission tomography imaging in stage II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?. <i>Leukemia and Lymphoma</i> , 2012, 53, 2143-2150. | 0.6 | 54        |
| 92  | Evaluation of the International Prognostic Score (IPS) and a Simpler Prognostic Score (IPS) for advanced Hodgkin lymphoma in the modern era. <i>British Journal of Haematology</i> , 2015, 171, 530-538.  | 1.2 | 54        |
| 93  | Assessment of knowledge about cancer pain management by physicians in training. <i>Journal of Pain and Symptom Management</i> , 1997, 14, 21-28.  | 0.6 | 53        |
| 94  | CD163 Immunohistochemistry Is Superior to CD68 in Predicting Outcome in Classical Hodgkin Lymphoma. <i>American Journal of Clinical Pathology</i> , 2014, 141, 381-387.   | 0.4 | 51        |
| 95  | Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. <i>Leukemia and Lymphoma</i> , 2014, 55, 2328-2334.  | 0.6 | 48        |
| 96  | Splenic Pathology in Myelodysplasia. <i>American Journal of Surgical Pathology</i> , 1998, 22, 1255-1266.   | 2.1 | 48        |
| 97  | Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase I Study. <i>Blood</i> , 2018, 132, 399-399.  | 0.6 | 48        |
| 98  | Anti-CD30 Antibodies for Hodgkin Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 140-147.  | 1.2 | 47        |
| 99  | Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. <i>Journal of Geriatric Oncology</i> , 2015, 6, 211-218.  | 0.5 | 47        |
| 100 | Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. <i>Cancer</i> , 2018, 124, 136-144.  | 2.0 | 47        |
| 101 | Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. <i>Leukemia and Lymphoma</i> , 2017, 58, 1607-1616.   | 0.6 | 46        |
| 102 | Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. <i>Leukemia and Lymphoma</i> , 2012, 53, 2283-2286.   | 0.6 | 44        |
| 103 | CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder. <i>American Journal of Transplantation</i> , 2021, 21, 809-814.   | 2.6 | 44        |
| 104 | Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial. <i>Blood</i> , 2020, 136, 42-44.   | 0.6 | 44        |
| 105 | Brentuximab Vedotin in Transplant-Naïve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies. <i>Oncologist</i> , 2012, 17, 1073-1080.  | 1.9 | 42        |
| 106 | Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 4149-4155.  | 2.5 | 42        |
| 107 | Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3025-3025.   | 0.8 | 42        |
| 108 | Brentuximab Vedotin and Crizotinib in Anaplastic Large-Cell Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> 1.0   | 1.0 | 41        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Progressive multifocal leukoencephalopathy treated with nivolumab. <i>Journal of NeuroVirology</i> , 2019, 25, 284-287.   | 1.0 | 40        |
| 110 | Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 858-867.   | 2.5 | 40        |
| 111 | First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. <i>Clinical Cancer Research</i> , 2020, 26, 2524-2534.  | 3.2 | 40        |
| 112 | Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 395-395.   | 0.6 | 40        |
| 113 | Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin's Disease. <i>Blood</i> , 2004, 104, 2635-2635.   | 0.6 | 39        |
| 114 | Brentuximab vedotin for the treatment of CD30 <sup>+</sup> lymphomas. <i>Immunotherapy</i> , 2011, 3, 475-485.  | 1.0 | 37        |
| 115 | Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. <i>Leukemia and Lymphoma</i> , 2015, 56, 2569-2578. | 0.6 | 36        |
| 116 | Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). <i>Leukemia and Lymphoma</i> , 2015, 56, 958-964.  | 0.6 | 36        |
| 117 | Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 234-234.   | 0.6 | 36        |
| 118 | Bone marrow staging in patients with non-hodgkin's lymphoma. , 1998, 82, 1154-1159.   |     | 35        |
| 119 | Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. <i>Blood</i> , 2019, 133, 1762-1765.   | 0.6 | 35        |
| 120 | Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. <i>British Journal of Haematology</i> , 2014, 165, 510-518.  | 1.2 | 34        |
| 121 | Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1936-1942.                                       | 0.8 | 33        |
| 122 | A Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results In Patients With DLBCL and Other B-Cell Lymphomas. <i>Blood</i> , 2013, 122, 848-848.   | 0.6 | 33        |
| 123 | Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas. <i>Blood</i> , 2012, 120, 60-60.  | 0.6 | 32        |
| 124 | Serum Markers in Germ Cell Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 1991, 5, 1245-1260.   | 0.9 | 31        |
| 125 | Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma. <i>Cancer</i> , 2001, 92, 207-217.  | 2.0 | 31        |
| 126 | Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw249.   | 3.0 | 31        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Multiple Complete Responses in a Phase I Dose-Escalation Study of the Antibody-Drug Conjugate SGN-35 in Patients with Relapsed or Refractory CD30-Positive Lymphomas.. Blood, 2008, 112, 1006-1006.   | 0.6 | 31        |
| 128 | Radiation Dosimetry Results From a Phase II Trial of Ibritumomab Tiuxetan (Zevalin®,) Radioimmunotherapy for Patients With Non-Hodgkin's Lymphoma and Mild Thrombocytopenia. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 165-178. | 0.7 | 30        |
| 129 | Blinatumomab for the treatment of B-cell lymphoma. Expert Opinion on Investigational Drugs, 2015, 24, 715-724.  | 1.9 | 30        |
| 130 | Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. British Journal of Haematology, 2017, 178, 250-256.                                    | 1.2 | 30        |
| 131 | Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial. Blood, 2014, 124, 800-800.  | 0.6 | 30        |
| 132 | Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1. Blood, 2016, 128, LBA-6-LBA-6.                                      | 0.6 | 30        |
| 133 | Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. Cancer, 2014, 120, 2122-2129.  | 2.0 | 29        |
| 134 | Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202. Blood, 2014, 124, 3091-3091.   | 0.6 | 28        |
| 135 | Intravascular lymphoma associated with endocrine dysfunction: a report of four cases and a review of the literature. American Journal of Medicine, 1999, 107, 169-176.  | 0.6 | 27        |
| 136 | Modern treatment of Hodgkin lymphoma. Current Opinion in Hematology, 2008, 15, 408-414.   | 1.2 | 27        |
| 137 | The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leukemia and Lymphoma, 2013, 54, 1405-1410.                 | 0.6 | 27        |
| 138 | The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials. Cancer Medicine, 2019, 8, 165-173.  | 1.3 | 27        |
| 139 | Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. Blood, 2021, 138, 639-639.  | 0.6 | 27        |
| 140 | Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. British Journal of Haematology, 2008, 140, 313-319.                            | 1.2 | 26        |
| 141 | A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leukemia and Lymphoma, 2011, 52, 587-596.  | 0.6 | 26        |
| 142 | Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clinical Cancer Research, 2019, 25, 1718-1726.  | 3.2 | 26        |
| 143 | Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia and Lymphoma, 2020, 61, 3188-3197.  | 0.6 | 26        |
| 144 | Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clinical Cancer Research, 2021, 27, 3339-3350.   | 3.2 | 26        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1. <i>Blood</i> , 2016, 128, 998-998.                      | 0.6 | 26        |
| 146 | Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1585-1585.  | 0.6 | 26        |
| 147 | Cyclin D1 as an Aid in the Diagnosis of Mantle Cell Lymphoma in Skin Biopsies: A Case Report. <i>American Journal of Dermatopathology</i> , 2001, 23, 470-476.  | 0.3 | 25        |
| 148 | CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 601-611.  | 1.9 | 25        |
| 149 | Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2013, 122, 1809-1809.  | 0.6 | 24        |
| 150 | Interdigitating dendritic reticulum cell tumor of lymph nodes: Case report with differential diagnostic considerations. <i>Diagnostic Cytopathology</i> , 2003, 28, 278-281.  | 0.5 | 23        |
| 151 | A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 347-353.   | 0.2 | 23        |
| 152 | Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403. <i>Blood</i> , 2015, 126, 337-337.                               | 0.6 | 23        |
| 153 | Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study. <i>Blood</i> , 2020, 136, 35-36.   | 0.6 | 23        |
| 154 | A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 875-882.   | 1.0 | 22        |
| 155 | The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.. <i>Blood</i> , 2009, 114, 2731-2731.                                       | 0.6 | 22        |
| 156 | Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 7512-7512.                      | 0.8 | 22        |
| 157 | Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604). <i>Blood</i> , 2015, 126, 578-578.  | 0.6 | 21        |
| 158 | Parameters for Validating a Hospital Pneumatic Tube System. <i>Clinical Chemistry</i> , 2019, 65, 694-702.  | 1.5 | 20        |
| 159 | Activity and tolerability of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7504-7504.                                   | 0.8 | 20        |
| 160 | Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7518-7518.                                       | 0.8 | 20        |
| 161 | Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study. <i>Blood</i> , 2021, 138, 127-127. | 0.6 | 20        |
| 162 | Anaplastic Large-Cell Lymphoma With Aberrant Expression of Multiple Cytokeratins Masquerading As Metastatic Carcinoma of Unknown Primary. <i>Journal of Clinical Oncology</i> , 2013, 31, e443-e445.  | 0.8 | 19        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria. <i>Leukemia and Lymphoma</i> , 2016, 57, 1191-1193.   | 0.6 | 18        |
| 164 | Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients. <i>Blood</i> , 2018, 131, 1698-1703.  | 0.6 | 18        |
| 165 | Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: <sc>CALGB</sc>/Alliance 50403. <i>American Journal of Hematology</i> , 2020, 95, 583-593.   | 2.0 | 18        |
| 166 | Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. <i>Blood</i> , 2018, 132, 6-6. | 0.6 | 18        |
| 167 | Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study. <i>Blood</i> , 2019, 134, 238-238.  | 0.6 | 18        |
| 168 | A Randomized Phase III Trial of ABVD Vs. Stanford V +/â” Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Blood</i> , 2010, 116, 415-415.  | 0.6 | 18        |
| 169 | Role of Routine Imaging in Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 575-584.   | 2.3 | 18        |
| 170 | Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers. <i>Therapeutic Advances in Hematology</i> , 2014, 5, 3-12.   | 1.1 | 17        |
| 171 | Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. <i>Blood</i> , 2022, 139, 1147-1159.   | 0.6 | 17        |
| 172 | Results of a Prospective Phase II Trial of Limited and Extended Rituximab Treatment in Nodular Lymphocyte Predominant Hodgkin's Disease (NLPHD).. <i>Blood</i> , 2007, 110, 644-644.  | 0.6 | 17        |
| 173 | Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 1105-1105.  | 0.6 | 17        |
| 174 | Phase 1/dose expansion trial of brentuximab vedotin andÂlenalidomide in relapsed or refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 139, 1999-2010.  | 0.6 | 17        |
| 175 | Antibodies for the treatment of diffuse large cell lymphoma. <i>Seminars in Oncology</i> , 2003, 30, 448-456.   | 0.8 | 15        |
| 176 | Therapy of Relapsed Hodgkin Lymphoma. <i>Blood Reviews</i> , 2007, 21, 233-243.   | 2.8 | 15        |
| 177 | Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 506-507.  | 0.6 | 15        |
| 178 | Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. <i>American Journal of Hematology</i> , 2016, 91, 894-899.   | 2.0 | 15        |
| 179 | Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1092-1106.   | 2.3 | 15        |
| 180 | Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies. <i>Cancer</i> , 2002, 95, 2223-2229.   | 2.0 | 14        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 181 | Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. <i>Lancet Haematology</i> , 2020, 7, e490-e497.  | 2.2 | 14        |
| 182 | Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2014, 124, 3095-3095.   | 0.6 | 14        |
| 183 | Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R. <i>Blood</i> , 2015, 126, 342-342.   | 0.6 | 14        |
| 184 | Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL). <i>Blood</i> , 2016, 128, 104-104.   | 0.6 | 14        |
| 185 | Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. <i>Lancet Haematology</i> , 2021, 8, e818-e827.   | 2.2 | 14        |
| 186 | Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701. <i>Blood</i> , 2021, 138, 523-523.  | 0.6 | 14        |
| 187 | Drug development for recurrent and refractory classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 529-540.  | 0.6 | 13        |
| 188 | PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001. <i>Blood</i> , 2019, 134, 349-349.  | 0.6 | 13        |
| 189 | Poor Predictive Value of FDG-PET/CT Performed after 2 Cycles of R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLCL). <i>Blood</i> , 2008, 112, 371-371.   | 0.6 | 13        |
| 190 | Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2010, 116, 961-961.  | 0.6 | 13        |
| 191 | SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial. <i>Blood</i> , 2016, 128, 2974-2974.  | 0.6 | 13        |
| 192 | Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7526-7526.  | 0.8 | 13        |
| 193 | Therapies for Relapsed Hodgkin Lymphoma: Transplant and Non-Transplant Approaches Including Immunotherapy. <i>Hematology American Society of Hematology Education Program</i> , 2005, 2005, 245-251.   | 0.9 | 12        |
| 194 | Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. <i>Leukemia</i> , 2021, 35, 2854-2861.  | 3.3 | 12        |
| 195 | A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data. <i>Blood</i> , 2018, 132, 1620-1620. | 0.6 | 12        |
| 196 | A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.. <i>Blood</i> , 2009, 114, 3693-3693.   | 0.6 | 12        |
| 197 | Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.. <i>Blood</i> , 2010, 116, 2800-2800.  | 0.6 | 12        |
| 198 | Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma. <i>Blood</i> , 2015, 125, 3354-3355.   | 0.6 | 11        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 199 | Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies. <i>Leukemia and Lymphoma</i> , 2015, 56, 1151-1153.  | 0.6  | 11        |
| 200 | ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. <i>Haematologica</i> , 2019, 104, e65-e67.   | 1.7  | 11        |
| 201 | Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 3623-3632.   | 2.5  | 11        |
| 202 | SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL). <i>Blood</i> , 2006, 108, 2718-2718.   | 0.6  | 11        |
| 203 | Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update. <i>Blood</i> , 2011, 118, 443-443.   | 0.6  | 11        |
| 204 | High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin A CALGB 59804 correlative study. <i>Leukemia and Lymphoma</i> , 2008, 49, 1202-1205. | 0.6  | 10        |
| 205 | Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). <i>Cancer</i> , 2019, 125, 3378-3389.   | 2.0  | 10        |
| 206 | Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. <i>American Journal of Surgical Pathology</i> , 2021, 45, 384-393.  | 2.1  | 10        |
| 207 | Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study. <i>Blood</i> , 2018, 132, 1647-1647.  | 0.6  | 10        |
| 208 | A Phase I Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia. <i>Blood</i> , 2006, 108, 2727-2727.   | 0.6  | 10        |
| 209 | A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2012, 120, 55-55.   | 0.6  | 10        |
| 210 | MACOP-B ± radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford Results According to Prognostic Indices. <i>Cancer</i> , 1993, 71, 4034-4042.  | 2.0  | 9         |
| 211 | Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: Results of CALGB 59906. <i>Leukemia and Lymphoma</i> , 2006, 47, 1511-1517.   | 0.6  | 9         |
| 212 | Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, 383-391.   | 0.6  | 9         |
| 213 | Fine-Tuning the Treatment of Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2016, 374, 2490-2492.  | 13.9 | 9         |
| 214 | Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 831-839.  | 1.4  | 9         |
| 215 | Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing). <i>Blood</i> , 2018, 132, 1635-1635.                        | 0.6  | 9         |
| 216 | A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results. <i>Blood</i> , 2012, 120, 2746-2746.  | 0.6  | 9         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 217 | Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2015, 126, 3991-3991.                       | 0.6 | 9         |
| 218 | A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 150-150.   | 0.6 | 9         |
| 219 | Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2016, 128, 4144-4144.  | 0.6 | 9         |
| 220 | Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. <i>Journal of Clinical Oncology</i> , 2023, 41, 336-342.   | 0.8 | 9         |
| 221 | Where Does Brentuximab Vedotin Fit into the Management of Patients with Hodgkin Lymphoma?. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 179-185.   | 1.2 | 8         |
| 222 | A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results. <i>Blood</i> , 2008, 112, 2595-2595.   | 0.6 | 8         |
| 223 | Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496. <i>Blood</i> , 2010, 116, 416-416.   | 0.6 | 8         |
| 224 | Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL). <i>Blood</i> , 2011, 118, 3711-3711.   | 0.6 | 8         |
| 225 | Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 821-833.  | 0.6 | 8         |
| 226 | Composite diffuse large B-cell lymphoma and precursor B lymphoblastic lymphoma presenting as a double-hit lymphoma with MYC and BCL2 translocation. <i>Journal of Clinical Pathology</i> , 2011, 64, 1032-1034.  | 1.0 | 7         |
| 227 | Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2199-2204.  | 2.0 | 7         |
| 228 | Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 317-323.  | 0.9 | 7         |
| 229 | Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study. <i>Leukemia and Lymphoma</i> , 2018, 59, 357-362.   | 0.6 | 7         |
| 230 | Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502. <i>Blood</i> , 2008, 112, 232-232.   | 0.6 | 7         |
| 231 | A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 1623-1623.   | 0.6 | 7         |
| 232 | Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study. <i>Blood</i> , 2021, 138, 3573-3573.                             | 0.6 | 7         |
| 233 | Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 793-798.   | 1.1 | 6         |
| 234 | Abstract CT146: First-in-human phase I combination of the IL-15 receptor super agonist complex ALT-803 with a therapeutic (anti-CD20) monoclonal antibody (mAb) for patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL). <i>Cancer Research</i> , 2018, 78, CT146-CT146. | 0.4 | 6         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 235 | Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach. <i>Blood</i> , 2018, 132, 929-929.  | 0.6 | 6         |
| 236 | Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma.. <i>Blood</i> , 2007, 110, 1351-1351.   | 0.6 | 6         |
| 237 | Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma.. <i>Blood</i> , 2009, 114, 2726-2726.  | 0.6 | 6         |
| 238 | Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL). <i>Blood</i> , 2010, 116, 4882-4882.   | 0.6 | 6         |
| 239 | Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.. <i>Blood</i> , 2012, 120, 2745-2745.   | 0.6 | 6         |
| 240 | Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas. <i>Blood</i> , 2013, 122, 4386-4386.  | 0.6 | 6         |
| 241 | Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation. <i>Blood</i> , 2015, 126, 2726-2726.  | 0.6 | 6         |
| 242 | Limited-Stage Hodgkin Lymphoma: Optimal Chemotherapy and the Role of Radiotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 374-380.  | 1.8 | 6         |
| 243 | Salvage regimens for Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 517-24.   | 0.3 | 6         |
| 244 | Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e435-e442.  | 0.2 | 6         |
| 245 | CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received 1 line of systemic therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7588-TPS7588. | 0.8 | 6         |
| 246 | Protein Losing Enteropathy Associated With Follicular Lymphoma of the Small Bowel. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 222-223.  | 0.6 | 5         |
| 247 | A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL). <i>Blood</i> , 2012, 120, 1644-1644.  | 0.6 | 5         |
| 248 | The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience. <i>Blood</i> , 2013, 122, 3060-3060.   | 0.6 | 5         |
| 249 | Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study. <i>Blood</i> , 2014, 124, 629-629.  | 0.6 | 5         |
| 250 | Frontline Treatment of CD30+ Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up. <i>Blood</i> , 2015, 126, 1537-1537.   | 0.6 | 5         |
| 251 | A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 3988-3988.   | 0.6 | 5         |
| 252 | Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study. <i>Blood</i> , 2016, 128, 1853-1853.   | 0.6 | 5         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 253 | Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2993-2993.                                       | 0.6 | 5         |
| 254 | Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8506-8506. | 0.8 | 5         |
| 255 | Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma. <i>Cancers</i> , 2022, 14, 2932.  | 1.7 | 5         |
| 256 | Treatment advances in non-Hodgkinâ€™s lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 451-465.   | 0.9 | 4         |
| 257 | Biologic Agents in the Management of Hodgkin Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 587-596.   | 2.3 | 4         |
| 258 | Fifty Shades of GATA2 Mutation: A Case of Plasmablastic Lymphoma, Nontuberculous Mycobacterial Infection, and Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e532-e535.  | 0.2 | 4         |
| 259 | Optimizing Second-Line Therapy for Hodgkin Lymphoma: A Work in Progress. <i>Journal of Clinical Oncology</i> , 2021, 39, 3097-3103.  | 0.8 | 4         |
| 260 | Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08). <i>Blood</i> , 2018, 132, 2964-2964.                                 | 0.6 | 4         |
| 261 | Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma. <i>Blood</i> , 2018, 132, 2892-2892.  | 0.6 | 4         |
| 262 | Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study. <i>Blood</i> , 2018, 132, 2904-2904.     | 0.6 | 4         |
| 263 | A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 586-586.   | 0.6 | 4         |
| 264 | Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. <i>Blood</i> , 2011, 118, 94-94.  | 0.6 | 4         |
| 265 | Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study. <i>Blood</i> , 2014, 124, 1745-1745.   | 0.6 | 4         |
| 266 | Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study. <i>Blood</i> , 2015, 126, 814-814.  | 0.6 | 4         |
| 267 | Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7541-7541.  | 0.8 | 4         |
| 268 | Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8003-8003.  | 0.8 | 4         |
| 269 | Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) â€“ Interim Analysis. <i>Blood</i> , 2010, 116, 1397-1397.                  | 0.6 | 4         |
| 270 | Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6). <i>Blood</i> , 2021, 138, 2832-2832.                         | 0.6 | 4         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 271 | Novel Genetic Subgroups Inform on Shared Pathobiology within Adult and Pediatric Burkitt Lymphoma. <i>Blood</i> , 2021, 138, 806-806.  | 0.6 | 4         |
| 272 | Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2020, 136, 3-4.  | 0.6 | 4         |
| 273 | The Present: Optimizing Therapy—Too Much or Too Little?. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 108-114.   | 0.9 | 3         |
| 274 | Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma. <i>OncoTargets and Therapy</i> , 2016, 9, 2027.   | 1.0 | 3         |
| 275 | SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 81-90.  | 0.2 | 3         |
| 276 | A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2223-2228.   | 2.0 | 3         |
| 277 | The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas. <i>Blood</i> , 2018, 132, 997-997.                     | 0.6 | 3         |
| 278 | Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial. <i>Blood</i> , 2019, 134, 1524-1524.                            | 0.6 | 3         |
| 279 | The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672). <i>Blood</i> , 2019, 134, 1591-1591. | 0.6 | 3         |
| 280 | Immuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909.. <i>Blood</i> , 2006, 108, 2737-2737.   | 0.6 | 3         |
| 281 | Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens. <i>Blood</i> , 2010, 116, 1753-1753.   | 0.6 | 3         |
| 282 | Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. <i>Blood</i> , 2011, 118, 1603-1603.                          | 0.6 | 3         |
| 283 | Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?.. <i>Blood</i> , 2011, 118, 3644-3644.   | 0.6 | 3         |
| 284 | Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. <i>Blood</i> , 2013, 122, 4277-4277.   | 0.6 | 3         |
| 285 | A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL). <i>Blood</i> , 2014, 124, 3099-3099.  | 0.6 | 3         |
| 286 | Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance). <i>Blood</i> , 2015, 126, 2741-2741.   | 0.6 | 3         |
| 287 | Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance). <i>Blood</i> , 2016, 128, 2953-2953.                               | 0.6 | 3         |
| 288 | Banoxantrone (AQ4N), a Tissue Targeted Prodrug: Results of a Phase 1 Study in Lymphomas.. <i>Blood</i> , 2006, 108, 2429-2429.   | 0.6 | 3         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 289 | Frontline Therapy of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Rituximab: The Stanford University Experience. <i>Blood</i> , 2011, 118, 2686-2686.  | 0.6 | 3         |
| 290 | Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance. <i>Blood</i> , 2021, 138, 2417-2417.   | 0.6 | 3         |
| 291 | Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. <i>Blood Advances</i> , 2022, 6, 2745-2756.  | 2.5 | 3         |
| 292 | Treatment of aggressive histology lymphoma. <i>Current Opinion in Oncology</i> , 1997, 9, 413-419.   | 1.1 | 2         |
| 293 | Hodgkin's disease: Prognostic factors and short-course regimens. <i>Current Oncology Reports</i> , 2000, 2, 163-171.   | 1.8 | 2         |
| 294 | Limited-Stage Hodgkin Lymphoma: Optimal Chemotherapy and the Role of Radiotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 374-380.   | 1.8 | 2         |
| 295 | Magnetic resonance image guided radiation therapy for primary splenic diffuse large B-cell lymphoma: A teaching case. <i>Practical Radiation Oncology</i> , 2017, 7, e23-e26.  | 1.1 | 2         |
| 296 | Protect our children: Hodgkin lymphoma survivors. <i>Blood</i> , 2021, 137, 1433-1434.   | 0.6 | 2         |
| 297 | Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS7571-TPS7571.   | 0.8 | 2         |
| 298 | Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2408-2415.   | 0.6 | 2         |
| 299 | CD3xCD20 bispecific T-cell redirectors for relapsed or refractory B-cell lymphoma. <i>Lancet, The</i> , 2021, 398, 1109-1110.  | 6.3 | 2         |
| 300 | Management of Advanced Stage Hodgkin's Lymphoma. , 2006, 131, 333-352.   |     | 2         |
| 301 | Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis. <i>Blood</i> , 2018, 132, 2927-2927.  | 0.6 | 2         |
| 302 | End of Treatment Peripheral Blood T-Cell Receptor Gene Rearrangement Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2020, 136, 30-31.   | 0.6 | 2         |
| 303 | Retrospective Analysis of the Safety and Efficacy of Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Hematologic Malignancies. <i>Blood</i> , 2012, 120, 3687-3687.   | 0.6 | 2         |
| 304 | Lack Of Clinical Benefit For Routine Surveillance Imaging For Diffuse Large B-Cell Lymphoma In First Complete Remission. <i>Blood</i> , 2013, 122, 4303-4303.  | 0.6 | 2         |
| 305 | Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab. <i>Blood</i> , 2015, 126, 2936-2936.   | 0.6 | 2         |
| 306 | Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401). <i>Blood</i> , 2015, 126, 334-334. | 0.6 | 2         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 307 | Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM). <i>Blood</i> , 2015, 126, 495-495.  | 0.6 | 2         |
| 308 | Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing. <i>Blood</i> , 2015, 126, 574-574.  | 0.6 | 2         |
| 309 | PIK3IP1 Inhibition of PI3K in G1 Arrest Induced By CDK4 Inhibition Reprograms MCL for Ibrutinib Therapy. <i>Blood</i> , 2016, 128, 610-610.   | 0.6 | 2         |
| 310 | Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7559-7559.            | 0.8 | 2         |
| 311 | Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7537-7537.   | 0.8 | 2         |
| 312 | The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A randomized phase 2 study of CDX-1127 (varlilumab) in combination with nivolumab in patients with relapsed or refractory aggressive B-cell lymphomas (NCI 10089/NCT03038672).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS7570-TPS7570. | 0.8 | 2         |
| 313 | Gray Zone Lymphoma (GZL) With Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective Multicenter Analysis Of Clinical Characteristics, Treatment, Outcomes, and Prognosis In The Current Era. <i>Blood</i> , 2013, 122, 847-847.       | 0.6 | 2         |
| 314 | Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2015, 126, 2730-2730.                                      | 0.6 | 2         |
| 315 | The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma. <i>Blood</i> , 2021, 138, 135-135.   | 0.6 | 2         |
| 316 | Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA7564-LBA7564.  | 0.8 | 2         |
| 317 | To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1027-1030.   | 0.5 | 1         |
| 318 | Approaches to aggressive B-cell lymphomas in less fit patients. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 140-147.   | 0.9 | 1         |
| 319 | Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. <i>Leukemia and Lymphoma</i> , 2020, 61, 2442-2447.  | 0.6 | 1         |
| 320 | The justification of vincristine dose capping: tradition, tradition, tradition!. <i>Leukemia and Lymphoma</i> , 2020, 61, 1007-1009.  | 0.6 | 1         |
| 321 | Treatment of Nodular Lymphocyte Hodgkin Lymphoma: The Goldilocks Principle. <i>Journal of Clinical Oncology</i> , 2020, 38, 662-668.  | 0.8 | 1         |
| 322 | A forgotten friend: CCNU as palliative monotherapy in relapsed Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 486-488.  | 0.6 | 1         |
| 323 | Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 3417-3417.   | 0.6 | 1         |
| 324 | Pralatrexate Reverses the Trend to Progressive Resistance to Successive Systemic Treatment Regimens In Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL). <i>Blood</i> , 2010, 116, 4881-4881.  | 0.6 | 1         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 343 | A Young Woman With Blurred Vision and Distal Paresthesias. <i>JAMA Neurology</i> , 2015, 72, 1519.   | 4.5 | 0         |
| 344 | Reply to T.M. Weis et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 2953-2953.   | 0.8 | 0         |
| 345 | Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7528-7528.  | 0.8 | 0         |
| 346 | A Phase II Study of Xcellerated T Cells <sup>®</sup> in Patients with Relapsed or Refractory Indolent Non-Hodgkin <sup>™</sup> s Lymphoma (NHL).. <i>Blood</i> , 2004, 104, 4640-4640.   | 0.6 | 0         |
| 347 | Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results.. <i>Blood</i> , 2008, 112, 1460-1460.   | 0.6 | 0         |
| 348 | Clonal Ig DNA Detection In Plasma From Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2010, 116, 3127-3127.   | 0.6 | 0         |
| 349 | Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years. <i>Blood</i> , 2012, 120, 4779-4779.  | 0.6 | 0         |
| 350 | Lymphoma Surveillance Counterpoint: USA. , 2013, , 461-466.  |     | 0         |
| 351 | Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients. <i>Blood</i> , 2013, 122, 1785-1785.  | 0.6 | 0         |
| 352 | Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome. <i>Blood</i> , 2014, 124, 1703-1703. | 0.6 | 0         |
| 353 | Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 3961-3961.  | 0.6 | 0         |
| 354 | Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN. <i>Blood</i> , 2015, 126, 1539-1539.  | 0.6 | 0         |
| 355 | Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial. <i>Blood</i> , 2016, 128, 4403-4403.   | 0.6 | 0         |
| 356 | Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas Including AITL and DLBCL: Phase I Results. <i>Blood</i> , 2018, 132, 2929-2929.   | 0.6 | 0         |
| 357 | Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration. <i>Blood</i> , 2018, 132, 2878-2878.  | 0.6 | 0         |
| 358 | Impact of Rituximab Infusion Reactions on Clinical Outcomes in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 4203-4203.   | 0.6 | 0         |
| 359 | Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis. <i>Blood</i> , 2019, 134, 4027-4027.   | 0.6 | 0         |
| 360 | Composite Copy Number Variation in CDK4, CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq. <i>Blood</i> , 2019, 134, 1492-1492.                               | 0.6 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 361 | North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1553-1553.   | 0.6 | 0         |
| 362 | Prognostic Factors Other Than Age Drive the Risk of Disease Progression in Adults with Burkitt Lymphoma Treated with DA-EPOCH-R. <i>Blood</i> , 2021, 138, 453-453.  | 0.6 | 0         |
| 363 | Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance]. <i>Blood</i> , 2020, 136, 50-50.                                 | 0.6 | 0         |
| 364 | Patient-Specific Metabolism Assessed By Visceral Fat and Diabetes May Alter Prognosis in Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 30-31.  | 0.6 | 0         |
| 365 | Stem cell transplant for lymphoma - never too late?. <i>Haematologica</i> , 2022, , .  | 1.7 | 0         |
| 366 | Advances in LLM: Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 468-71.  | 0.3 | 0         |
| 367 | Commentary. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 18-23.   | 0.3 | 0         |
| 368 | Radiation for early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a double-edged sword?. <i>Leukemia and Lymphoma</i> , 2016, 57, 249-251.  | 0.6 | 0         |
| 369 | Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7593-TPS7593. | 0.8 | 0         |